January 29, 2018 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, announced today that Marvin Washington, brand ambassador and spokesman for Isodiol, will be speaking on the cause of the neurological disorder Chronic Traumatic Encephalopathy (CTE) at Super Bowl LII.
Mr. Washington will be in Minneapolis before the Super Bowl to draw attention to the silent killer of football players in the National Football League. Together, through the Company’s brand ISO-Sport, the goal is to raise awareness about CTE and the dangers of player concussions.
“Players are dying from CTE,” said Mr. Washington, a defensive end in the National Football League for eleven seasons, 1989-1999. “I want to sound the alarm about CTE, and let the world know there is a way to protect the brains of players and stop the damage with CBD.”
In an interview with i24NEWS, Mr. Washington added, “The US government has a patent that says a cannabinoid in a cannabis plant can be used as an antioxidant or protective for the brain and that is what I take. The leading cannabidiol company in the world is Isodiol and I have aligned with them, and we have taken this all the way to the body that represents the former players, which is the National Football League Players Association.”
To view this interview from January 26, 2018, please visit i24news.
Mr. Washington, who won a Super Bowl ring with the Denver Broncos in 1999, is now a crusader for the healing powers of cannabis with Isodiol. The company is actively developing non-psychoactive cannabinoids to work as neuroprotectants for athletes on the football field.
“This is a matter of life and death,” said Mr. Washington. “The science is there. The proof is there. We need to protect players, and I believe Cannabidiol – “CBD” is the solution.”
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
“Marcos Agramont” CEO & Director
COMPANY MEDIA :
North 6th Agency
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.